drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Lentiviral CAR T cells targeting CD2; dose-escalated IV infusion; mediates MHC-independent killing of CD2+ T-cell malignancies via perforin/granzyme release and cytokine-driven clearance.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Lentivirally engineered T cells expressing a CD2-specific chimeric antigen receptor bind CD2 on malignant T cells in an MHC-independent manner, triggering T‑cell activation and cytotoxicity with perforin/granzyme release and cytokine-driven tumor clearance after IV infusion.
drug_name
CD2-directed CAR T cells
nct_id_drug_ref
NCT06849921